- Report
- January 2024
- 200 Pages
Japan
From €5163EUR$5,750USD£4,396GBP
- Report
- April 2024
- 180 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- December 2022
- 112 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Drug Pipelines
- May 2023
- 151 Pages
Global
From €13463EUR$14,995USD£11,465GBP
- Report
- May 2020
- 218 Pages
Global
From €13463EUR$14,995USD£11,465GBP
- Report
- March 2025
- 111 Pages
China
From €1616EUR$1,800USD£1,376GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €19753EUR$22,000USD£16,821GBP
- Report
- June 2025
- 50 Pages
Global
From €2379EUR$2,650USD£2,026GBP
- Report
- March 2025
- 239 Pages
China
From €3591EUR$4,000USD£3,058GBP
- Report
- November 2021
- 575 Pages
Global
From €3591EUR$4,000USD£3,058GBP
Donepezil is a drug used to treat Alzheimer's Disease, a progressive neurological disorder that affects memory and cognitive function. It is a cholinesterase inhibitor, meaning it works by increasing the amount of the neurotransmitter acetylcholine in the brain. This helps to improve memory and cognitive function in people with Alzheimer's Disease. Donepezil is available in both oral and transdermal forms, and is usually taken once a day. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and diarrhea.
Donepezil is one of the most commonly prescribed drugs for Alzheimer's Disease, and is widely available in many countries. It is often used in combination with other drugs to treat the symptoms of Alzheimer's Disease.
Companies in the Donepezil market include Pfizer, Eisai, Mylan, and Teva Pharmaceuticals. Show Less Read more
